Steven Argumedo, MD
Internal Medicine · San Antonio, TXNPI 1780864751
Payments from drug & device makers
Across 339 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$760
- AstraZeneca$646
- GSK$469
- Sanofi-aventis U.S. LLC$402
- Lilly USA, LLC$399
- Boehringer Ingelheim$318
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $760 |
| AstraZeneca | 36 | $646 |
| GSK | 36 | $469 |
| Sanofi-aventis U.S. LLC | 20 | $402 |
| Lilly USA, LLC | 22 | $399 |
| Boehringer Ingelheim | 18 | $318 |
| AbbVie | 36 | $305 |
| Sunovion Pharmaceuticals Inc. | 16 | $235 |
| Novartis | 12 | $231 |
| Merck | 23 | $211 |
| Johnson & Johnson | 11 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $130 |
| Abbott | 4 | $90 |
| Arbor Pharmaceuticals, Inc. | 6 | $83 |
| Pfizer | 5 | $60 |
| Intercept Pharmaceuticals, Inc. | 2 | $37 |
| Amgen | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Exact Sciences | 1 | $22 |
| Globus Medical | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Intuitive Surgical | 1 | $13 |
| Acclarent, Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$117
- Ozempic$113
- RYBELSUS$113
- SOLIQUA 100/33$112
How this compares
$4,776 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 189 | $343,884 |
| TrulicityDulaglutide | 165 | $336,255 |
| JardianceEmpagliflozin | 166 | $257,718 |
| MounjaroTirzepatide | 94 | $161,758 |
| JanuviaSitagliptin Phosphate | 91 | $132,565 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 141 | $108,569 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $73,428 |
| FarxigaDapagliflozin Propanediol | 45 | $48,380 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $46,561 |
| EliquisApixaban | 39 | $45,666 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 40 | $41,078 |
| XareltoRivaroxaban | 30 | $40,068 |
| LinzessLinaclotide | 46 | $36,502 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $36,203 |
| MyrbetriqMirabegron | 41 | $34,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $399 | $498,013259 claims |
| Novo NordiskOzempic | $760 | $343,884189 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy | $318 | $334,414240 claims |
| MerckJanuvia, Janumet Xr, Janumet, Lagevrio (Eua) | $211 | $193,908142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $469 | $91,243101 claims |
| AbbVieLinzess, Creon | $305 | $67,04276 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $646 | $62,63774 claims |
| PfizerEliquis | $60 | $45,66639 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $402 | $41,07840 claims |
| Johnson & JohnsonXarelto | $160 | $40,06830 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $34,21641 claims |
| NovartisEntresto | $231 | $27,45119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in San Antonio
- Robert BassSan Antonio$25.6M
- Hernan SalazarSan Antonio$18.5M
- Dennis RuffSan Antonio$7.5M
- Cassandra KeySan Antonio$5.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.